Autolus Therapeutics (AUTL) Return on Sales (2017 - 2025)
Autolus Therapeutics' Return on Sales history spans 9 years, with the latest figure at 3.72% for Q4 2025.
- For Q4 2025, Return on Sales rose 94821.0% year-over-year to 3.72%; the TTM value through Dec 2025 reached 3.81%, up 1797.0%, while the annual FY2025 figure was 3.81%, 1799.0% up from the prior year.
- Return on Sales reached 3.72% in Q4 2025 per AUTL's latest filing, roughly flat from 3.73% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 2.29% in Q2 2025 to a low of 951.93% in Q4 2024.
- Average Return on Sales over 5 years is 224.17%, with a median of 69.76% recorded in 2021.
- Peak YoY movement for Return on Sales: tumbled -82921bps in 2024, then soared 94821bps in 2025.
- A 5-year view of Return on Sales shows it stood at 69.76% in 2021, then crashed by -1186bps to 896.79% in 2022, then surged by 86bps to 122.72% in 2023, then crashed by -676bps to 951.93% in 2024, then skyrocketed by 100bps to 3.72% in 2025.
- Per Business Quant, the three most recent readings for AUTL's Return on Sales are 3.72% (Q4 2025), 3.73% (Q3 2025), and 2.29% (Q2 2025).